Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Paper
  • Published:

Effects of PYY[3–36] in rodent models of diabetes and obesity

International Journal of Obesity volume 28, pages 963–971 (2004)Cite this article

Abstract

BACKGROUND: Peptide YY (PYY) is a 36 amino-acid peptide secreted from ileal L cells following meals. The cleaved subpeptide PYY[3–36] is biologically active and may constitute the majority of circulating PYY-like immunoreactivity. The peptide family that includes PYY, pancreatic peptide and neuropeptide Y is noted for its orexigenic effect following intracerebroventricular administration.

OBJECTIVE: To investigate the effects of peripheral (intraperitoneal and chronic subcutaneous) infusions of PYY[3–36] on food intake, body weight and glycemic indices.

DESIGN/RESULTS: Food intake was measured in normal mice and in several rodent models of obesity and type II diabetes. In marked contrast to the reported central orexigenic effects, in the present study, PYY[3–36] acutely inhibited food intake by up to 45%, with an ED50 of 12.5 μg/kg in fasted female NIH/Swiss mice. A 4-week infusion reduced weight gain in female ob/ob mice, without affecting the cumulative food intake. In diet-induced obese male mice, PYY[3–36] infusion reduced cumulative food intake, weight gain and epididymal fat weight (as a fraction of carcass) with similar ED50's (466, 297 and 201 μg/kg/day, respectively) and prevented a diet-induced increase in HbA1c. Infusion at 100 μg/kg/day for 8 weeks in male fa/fa rats reduced the weight gain (288±11 vs 326±12 g in saline-infused controls; P<0.05), similar to effects in a pair-fed group. In female ob/ob and db/db mice, there was no acute effect of PYY[3-36] on plasma glucose concentrations. In male diabetic fatty Zucker rats, PYY[3–36] infused for 4 weeks reduced HbA1c and fructosamine (ED50's 30 and 44 μg/kg/day).

CONCLUSION: Peripheral PYY[3–36] administration reduced the food intake, body weight gain and glycemic indices in diverse rodent models of metabolic disease of both sexes. These findings justify further exploration of the potential physiologic and therapeutic roles of PYY[3–36].

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

Similar content being viewed by others

References

  1. Adrian TE, Bacarese-Hamilton AJ, Smith HA, Chohan P, Manolas KJ, Bloom SR . Distribution and postprandial release of porcine peptide YY. J Endocrinol 1987; 113: 11–14.

    Article  CAS  Google Scholar 

  2. Adrian TE, Ferri GL, Bacarese-Hamilton AJ, Fuessl HS, Polak JM, Bloom SR . Human distribution and release of a putative new gut hormone, peptide YY. Gastroenterology 1985; 89: 1070–1077.

    Article  CAS  Google Scholar 

  3. Eberlein GA, Eysselein VE, Schaeffer M, Layer P, Grandt D, Goebell H, Niebel W, Davis M, Lee TD, Shively JE . A new molecular form of PYY: structural characterization of human PYY(3–36) and PYY(1–36). Peptides 1989; 10: 797–803.

    Article  CAS  Google Scholar 

  4. Grandt D, Schimiczek M, Beglinger C, Layer P, Goebell H, Eysselein VE, Reeve Jr JR . Two molecular forms of peptide YY (PYY) are abundant in human blood: characterization of a radioimmunoassay recognizing PYY 1–36 and PYY 3–36. Regul Pept 1994; 51: 151–159.

    Article  CAS  Google Scholar 

  5. Clark JT, Kalra PS, Crowley WR, Kalra SP . Neuropeptide Y and human pancreatic polypeptide stimulate feeding behavior in rats. Endocrinology 1984; 115: 427–429.

    Article  CAS  Google Scholar 

  6. Clark JT, Sahu A, Kalra PS, Balasubramaniam A, Kalra SP . Neuropeptide Y (NPY)-induced feeding behavior in female rats: comparison with human NPY ([Met17]NPY), NPY analog ([norLeu4]NPY) and peptide YY. Regul Pept 1987; 17: 31–39.

    Article  CAS  Google Scholar 

  7. Morley JE, Levine AS, Grace M, Kneip J . Peptide YY (PYY), a potent orexigenic agent. Brain Res 1985; 341: 200–203.

    Article  CAS  Google Scholar 

  8. Marsh DJ, Hollopeter G, Kafer KE, Palmiter RD . Role of the Y5 neuropeptide Y receptor in feeding and obesity. Nat Med 1998; 4: 718–721.

    Article  CAS  Google Scholar 

  9. Kanatani A, Mashiko S, Murai N, Sugimoto N, Ito J, Fukuroda T, Fukami T, Morin N, MacNeil DJ, Van der Ploeg LH, Saga Y, Nishimura S, Jhara M . Role of the Y1 receptor in the regulation of neuropeptide Y-mediated feeding: comparison of wild-type, Y1 receptor-deficient, and Y5 receptor-deficient mice. Endocrinology 2000; 141: 1011–1016.

    Article  CAS  Google Scholar 

  10. Batterham RL, Cowley MA, Small CJ, Herzog HH, Cohen MA, Dakin CL, Wren AM, Kennedy AR, Low MJ, Ghatei MA, Cone RD, Bloom SR . PYY[3–36], a gut hormone, physiologically inhibits food intake in rodents and man. Proc Endocr Soc 2002. OR 44-1.

  11. Batterham RL, Cohen MA, Ellis SM, Le Roux CW, Withers DJ, Frost GS, Ghatei MA, Bloom SR . Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med 2003; 349: 941–948.

    Article  CAS  Google Scholar 

  12. Bhavsar S, Hoyt J, Paterniti JR . Continuous infusion of PYY reduces food consumption and body weight in Fatty Zucker (fa/fa) rats. Diabetes 2002; 51 (Suppl 1): A602.

    Google Scholar 

  13. Hoyt J, Bhavsar S, Young AA . Effect of continuous infusion of PYY[3–36] on food intake and body weight in ob/ob (B6VLepob) mice. Diabetes 2002; 51 (Suppl 2): A418 (abstract #1716-P).

    Google Scholar 

  14. Bhavsar S, Parkes D, Hoyt J, Reynolds J, Paterniti JR, Young AA . PYY decreases food consumption and improves glycemic control in Zucker Diabetes Fatty (ZDF) rats. Diabetes 2002; 51 (Suppl 1): A418–A419.

    Google Scholar 

  15. Moore C, Jodka C, Dang JT, Lwin A, Young A . Chronic administration of PYY reduces body weight and improves glycemic control in C57BL/6J mice fed a high fat diet. Diabetes 2002; 51 (Suppl 2): A419.

    Google Scholar 

  16. Batterham RL, Cowley MA, Small CJ, Herzog H, Cohen MA, Dakin CL, Wren AM, Brynes AE, Low MJ, Ghatei MA, Cone RD, Bloom SR . Gut hormone PYY[3–36] physiologically inhibits food intake. Nature 2002; 418: 650–654.

    Article  CAS  Google Scholar 

  17. Corp ES, Greco B, Powers JB, Bivens CL, Wade GN . Neuropeptide Y inhibits estrous behavior and stimulates feeding via separate receptors in Syrian hamsters. Am J Physiol Regul Integr Comp Physiol 2001; 280: R1061–R1068.

    Article  CAS  Google Scholar 

  18. Dumont Y, Fournier A, St-Pierre S, Quirion R . Autoradiographic distribution of Leu31,Pro34 PYY and [PYY3–36] binding sites in the rat brain evaluated with two newly developed Y1 and Y2 receptor radioligands. Synapse 1996; 22: 139–158.

    Article  CAS  Google Scholar 

  19. Bird E, Cardone CC, Contreras RJ . Area postrema lesions disrupt food intake induced by cerebroventricular infusions of 5-thioglucose in the rat. Brain Res 1983; 270: 193–196.

    Article  CAS  Google Scholar 

  20. Young A, Gedulin B, Srivastava V, Jodka C, Nikoulina S . PeptideYY inhibits gastric emptying via a neuroendocrine pathway that includes the area postrema. Diabetes 2002; 51 (Suppl 2): A405.

    Google Scholar 

  21. Leslie RA, McDonald TJ, Robertson HA . Autoradiographic localization of peptide YY and neuropeptide Y binding sites in the medulla oblongata. Peptides 1988; 9: 1071–1076.

    Article  CAS  Google Scholar 

  22. Lynch DR, Walker MW, Miller RJ, Snyder SH . Neuropeptide Y receptor binding sites in rat brain: differential autoradiographic localizations with 125I-peptide YY and 125I-neuropeptide Y imply receptor heterogeneity. J Neurosci 1989; 9: 2607–2619.

    Article  CAS  Google Scholar 

  23. Bonaz B, Taylor I, Tache Y . Peripheral peptide YY induces c-fos-like immunoreactivity in the rat brain. Neurosci Lett 1993; 163: 77–80.

    Article  CAS  Google Scholar 

  24. Chen CH, Rogers RC . Central inhibitory action of peptide YY on gastric motility in rats. Am J Physiol 1995; 269 (Part 2): R787–R792.

    CAS  PubMed  Google Scholar 

  25. Yang H . Central and peripheral regulation of gastric acid secretion by peptide YY. Peptides 2002; 23: 349–358.

    Article  CAS  Google Scholar 

  26. Deng X, Guarita DR, Pedroso MR, Wood PG, Kreiss C, Sved AF, Whitcomb DC . Area postrema lesion alters the effects of peptide YY on 2-DG-stimulated pancreatic exocrine secretion. Dig Dis Sci 2001; 46: 2460–2469.

    Article  CAS  Google Scholar 

  27. Deng X, Guarita DR, Pedroso MR, Kreiss C, Wood PG, Sved AF, Whitcomb DC . PYY inhibits CCK-stimulated pancreatic secretion through the area postrema in unanesthetized rats. Am J Physiol Regul Integr Comp Physiol 2001; 281: R645–R653.

    Article  CAS  Google Scholar 

  28. Harding RK, McDonald TJ . Identification and characterization of the emetic effects of peptide YY. Peptides 1989; 10: 21–24.

    Article  CAS  Google Scholar 

  29. Grill HJ, Kaplan JM . The neuroanatomical axis for control of energy balance. Front Neuroendocrinol 2002; 23: 2–40.

    Article  CAS  Google Scholar 

  30. Nikoulina S, Gedulin B, Smith P, Young A . Effect of PYY on gastric acid secretion and gastro protection in rats. Diabetes 2002; 51 (Suppl 2): A590.

    Google Scholar 

  31. Pittner RA, Young AA, Paterniti JR, inventors; Amylin Pharmaceuticals Inc., assignee. Peptide YY, peptide YY agonists for the treatment of metabolic disorders. US Patent Application WO 02/47712 A2, 2000.

  32. Savage AP, Adrian TE, Carolan G, Chatterjee VK, Bloom SR . Effects of peptide YY (PYY) on mouth to caecum intestinal transit time and on the rate of gastric emptying in healthy volunteers. Gut 1987; 28: 166–170.

    Article  CAS  Google Scholar 

  33. Pappas TN, Debas HT, Chang AM, Taylor IL . Peptide YY release by fatty acids is sufficient to inhibit gastric emptying in dogs. Gastroenterology 1986; 91: 1386–1389.

    Article  CAS  Google Scholar 

  34. Allen JM, Fitzpatrick ML, Yeats JC, Darcy K, Adrian TE, Bloom SR . Effects of peptide YY and neuropeptide Y on gastric emptying in man. Digestion 1984; 30: 255–262.

    Article  CAS  Google Scholar 

  35. Pappas TN, Debas HT, Goto Y, Taylor IL . Peptide YY inhibits meal-stimulated pancreatic and gastric secretion. Am J Physiol 1985; 248 (Part 1): G118–G123.

    CAS  PubMed  Google Scholar 

  36. Lloyd KCK, Grandt D, Aurang K, Eysselein VE, Schimiczek M, Reeve JR . Inhibitory effect of PYY on vagally stimulated acid secretion is mediated predominantly by Y-1 receptors. Am J Physiol 1996; 270 (Part 1): G123–G127.

    CAS  PubMed  Google Scholar 

  37. Adrian TE, Savage AP, Sagor GR, Allen JM, Bacarese-Hamilton AJ, Tatemoto K, Polak JM, Bloom SR . Effect of peptide YY on gastric, pancreatic, and biliary function in humans. Gastroenterology 1985; 89: 494–499.

    Article  CAS  Google Scholar 

  38. Greeley JR GH, Guo YS, Gomez G, Lluis F, Singh P, Thompson JC . Inhibition of gastric acid secretion by peptide YY is independent of gastric somatostatin release in the rat. Proc Soc Exp Biol Med 1988; 189: 325–328.

    Article  CAS  Google Scholar 

  39. Gue M, Junien JL, Reeve Jr JR, Rivier J, Grandt D, Tache Y . Reversal by NPY, PYY and 3–36 molecular forms of NPY and PYY of intracisternal CRF-induced inhibition of gastric acid secretion in rats. Br J Pharmacol 1996; 118: 237–242.

    Article  CAS  Google Scholar 

  40. Yoshinaga K, Mochizuki T, Yanaihara N, Oshima K, Izukura M, Kogire M, Sumi S, Gomez G, Uchida T, Thompson JC et al. Structural requirements of peptide YY for biological activity at enteric sites. Am J Physiol 1992; 263 (Part 1): G695–G701.

    CAS  PubMed  Google Scholar 

  41. Guan D, Maouyo D, Taylor IL, Gettys TW, Greeley JR GH, Morisset J . Peptide-YY, a new partner in the negative feedback control of pancreatic secretion. Endocrinology 1991; 128: 911–916.

    Article  CAS  Google Scholar 

  42. Hoentjen F, Hopman WP, Jansen JB . Effect of circulating peptide YY on gallbladder motility in response to feeding in humans. Program and Abstracts, Digestive Disease Week, May 20–23, 2001, Atlanta, GA 2001. (abstract 65).

  43. Lutz TA, Del Prete E, Scharrer E . Reduction of food intake in rats by intraperitoneal injection of low doses of amylin. Physiol Behav 1994; 55: 891–895.

    Article  CAS  Google Scholar 

  44. Riddle MC . Pramlintide: an agent for glycemic control plus weight control? Diabetes Technol Ther 2002; 4: 63–65.

    Article  CAS  Google Scholar 

  45. Ratner RE, Want LL, Fineman MS, Velte MJ, Ruggles JA, Gottlieb A, Weyer C, Kolterman OG . Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with type 2 diabetes. Diabetes Technol Ther 2002; 4: 51–61.

    Article  CAS  Google Scholar 

  46. Hollander PA, Levy P, Fineman MS, Maggs DG, Shen LZ, Strobel SA, Weyer C, Kolterman OG . Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care 2003; 26: 784–790.

    Article  CAS  Google Scholar 

  47. Young A, Moore C, Herich J, Beaumont K . Chapter 9: Neuroendocrine actions of amylin. In: Poyner D, Marshall I, Brain SD (eds). The CGRP family: calcitonin gene-related peptide (CGRP), amylin, and adrenomedullin. Landes Bioscience: Georgetown, TX; 2000. pp 91–102.

    Google Scholar 

  48. Clark JB, Palmer CJ, Shaw WN . The diabetic Zucker fatty rat. Proc Soc Exp Biol Med 1983; 173: 68–75.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We gratefully acknowledge the technical contributions of Julie Hoyt, Jim Reynolds, Jean Dang, Aung Lwin and Giuseppe DelloIacono to the experiments reported herein.

Author information

Authors and Affiliations

  1. Amylin Pharmaceuticals, Inc, San Diego, CA, USA

    R A Pittner, C X Moore, S P Bhavsar, B R Gedulin, P A Smith, C M Jodka, D G Parkes, J R Paterniti, V P Srivastava & A A Young

Authors
  1. R A Pittner
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C X Moore
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S P Bhavsar
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. B R Gedulin
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. P A Smith
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. C M Jodka
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. D G Parkes
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. J R Paterniti
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. V P Srivastava
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. A A Young
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A A Young.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pittner, R., Moore, C., Bhavsar, S. et al. Effects of PYY[3–36] in rodent models of diabetes and obesity. Int J Obes 28, 963–971 (2004). https://doi.org/10.1038/sj.ijo.0802696

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.ijo.0802696

Keywords

This article is cited by

Search

Advanced search

Quick links